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PHYSICIANS’ ATTITUDES TO AND EXPERIENCE WITH
INCREASED USE OF INDIVIDUAL REIMBURSEMENT VERSUS
GENERAL REIMBURSEMENT OF NEW IMPORTANT
PHARMACEUTICALS
Levorsen A1, Kristiansen IS2,Aasland OG3
1Oslo University/ MSD Norway, Oslo, Norway, 2Oslo University, Oslo,
Norway, 3Oslo University/ Norwegian Medical Association, Oslo,
Norway
OBJECTIVES: In 2003 a restrictive reimbursement scheme,
advocating increased individual reimbursement versus general
reimbursement of new important pharmaceuticals, was imple-
mented in Norway. This study was conducted 18 months after
implementation, and investigates physician self-reported atti-
tudes to and experience with the scheme from a clinical and
administrative perspective. METHODS: Practicing physicians (n
= 1399) from the NMA Research Panel were surveyed (73 ques-
tion self-administered questionnaire) by mail, December 2004.
The response rate was 71% (n = 993). Only data from respon-
dents involved with the scheme in 2004 (n = 605; 61%) were
analysed in this sub-study of 24 questions. Physicians’ attitudes
and experience were addressed through 17 claims about the
scheme and evaluated on Likert scales, in addition to questions
on resource use and number of applications, referrals and appli-
cation approvals/rejections. RESULTS: Of the 605 respondents
in this sub-study, 87% agreed that the individual reimbursement
scheme was complicated and demanding. Only 37% reported
approval of all applications. Rejected applications were appealed
by 26% of the physicians, 31% re-submitted/-referred to spe-
cialists, 22% requested written justiﬁcation, 21% recommended
patients to pay for the pharmaceutical themselves, whilst 14%
did nothing. The majority of physicians (71%) were dissatisﬁed
with the scheme and 54% were dissatisﬁed with the application-
process. In contrast, only 11% were satisﬁed with the scheme
and 14% with the application-process. Fifty-seven percent
reported that the scheme restricted physicians from prescribing
the pharmaceutical they consider clinically best for a patient and
52% of patients choose to pay for the pharmaceutical them-
selves. Self-reported use of time to administrate individual appli-
cations (n = 110,000), was estimated to 11 physician-labour
years and a cost of 42 million NOK in 2004. CONCLUSIONS:
The majority of physicians in Norway are dissatisﬁed with the
governments increased use of individual reimbursement. The
results indicate that the scheme generates high administrative
costs and may have negative consequences for patients.
PHP35
TELEMEDICINE IN THE U.S. MEDICARE PROGRAM: 2007
REIMBURSEMENT IMPLICATIONS
Pierce CA1, Baker JJ2, McClard C2
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OBJECTIVE: Reform legislation has expanded the U.S.
Medicare program for eligible telemedicine services and has
required establishment of a process to add or delete covered ser-
vices on an annual basis. This study explores the current reim-
bursement status of Medicare telemedicine reimbursement and
its potential implications for 2007. METHODS: The Medicare
rationale and historic progress of telemedicine coverage and
reimbursement was constructed within a worksheet format.
Major changes and additions to the program were highlighted
and examined. A timeline of legislative and regulatory decisions
was prepared. Criteria for coverage and payment were identiﬁed
and summarized. Current deﬁnitions of required equipment and
exceptions to these requirements were identiﬁed and their evo-
lution tracked. The potential for 2007 reimbursement changes
was evaluated. RESULTS: A summary of ﬁndings follows. The
Medicare telemedicine program contains four major covered
types of service that can now be performed by eight categories
of speciﬁed professionals. Two types of geographic areas are eli-
gible, although certain demonstration programs may be eligible
regardless of geographic location. Billing and payment requires
the use of stipulated codes. The process to add or delete services
annually has been implemented. Each transaction must contain
two sites; “distant” and “originating”. There are ﬁve types of
originating sites. Payment is funded differently for “distant”
versus “originating”. The required equipment is primarily rep-
resented by interactive telecommunications systems, although
asynchronous technology is allowed in restricted instances. An
upcoming Medicare report to Congress may recommend further
expansion of the telemedicine program in 2007. CONCLU-
SIONS: Medicare telemedicine coverage and payment has con-
tinued to expand but remains restricted to certain geographic
areas and to certain service provider sites. Health care decision-
makers, including managers and payers, must be made better
aware of the multiple beneﬁts and efﬁciencies that telemedicine
offers to both service providers and to patients.
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PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE USEING
DRUGS FROM REIMBESMENT LIST IN RUSSIA
Yagudina RI1, Kulikov A1, Safﬁulin R2,Yarkaeva F2
1Moscow Medical Academy, Moscow, Russia, 2Kazan Medical
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OBJECTIVES: To estimate volumes and structure of consump-
tion of the drugs received by separate categories of citizens which
have the right to free-of-charge reception under reimbesment
program (DLO) in 2005 in Tatarstan (on example Tatarstan
region). To allocate diseases having the greatest prevalence and-
or the greatest ﬁnancial loading for budget. METHODS: In 2004
there was not the federal reimbursement system. In 2005 DLO
was launched. A total of 216,722 persons have the right to
receive drugs by DLO. We received the information on each of
2,543,599 purposes of drugs. Ischemic illness of heart, hyper-
tonic illness, diabetes, cancer of a mammary gland were leaders
on volume. Expenses Ischemic illness of heart, hypertonic illness,
diabetes, cancer of a mammary gland were leaders on volume 
of expense. One thousand patients with these diagnosis were 
randomized. We compared their therapy in 2004 vs. 2005.
RESULTS: Total cost of DLO in Tatarstan in 2005 was
€26,368,244. Average cost of one recipe in 2005 in DLO was
€10.5. Average expenses for one patient in 2005 a year in DLO
was €124. The maximal expenses for one patient was €23,534.
On ischemic illness of heart 7% of charges are necessary, arter-
ial hypertension 9%, diabetes 16%, oncology 19%. CONCLU-
SION: Introduction of system of reimbesment has rendered
beneﬁcial effect on quality of treatment of patients 2005 vs. 2004
percentage of patients on a regular basis received drug therapy
in occasion of cardiovascular diseases (with the miss no more
than three months for a year) has grown from 15,8% up to
32.8%.
PHP37
GENERIC COMPETITION: EFFECT ON PRICES AND
SUBSTITUTION EFFECTS
Engstrom A, Lundin D, Jacob J
LFN Pharmaceutical Beneﬁts Board, Solna, Sweden
OBJECTIVES: To calculate a price index for pharmaceuticals in
Sweden and to examine the effects of generic competition on
patented pharmaceuticals. METHODS: Price and volume data
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for the period 2002–2005, for the 180 most selling substances
were used to calculate a chain price index. A regression model
was used to estimate the effects of analog substitution, i.e
switches from one substance to another of the same class, for 
5 major products whose patent expired during the period.
RESULTS: The general price level of pharmaceuticals has fallen
15% during the period and off-patent drugs have experienced a
40% fall in price level. In addition to the direct effect on prices
of a substance due to generic competition, there has also been
analog substitution effect from patented drugs to off-patent
drugs. For two groups of pharmaceuticals, statins and PPIs, there
were signiﬁcant substitution effects between substances due to
the changes in relative prices. CONCLUSIONS: Generic substi-
tution in Sweden has been effective in reducing prices of off-
patent pharmaceuticals. Generic substitution has also had more
farreaching effects than what has been previously believed. There
has been a move from patented to off-patent products within the
same therapeutic area.
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HEALTH TECHNOLOGY ASSESSMENT IN HUNGARY
Nádudvari N
National Institute for Strategic Health Research, Budapest, Hungary
OBJECTIVE: Hungary’s accession to the European Union in
May 2004 compelled reconsideration of the social insurance
inclusion of pharmaceutical products. The Ofﬁce of Health Tech-
nology Assessment (HTA) of the National Institute for Strategic
Health Research was formed in 2004 with the aim of establish-
ing an independent institution to support decision-makers in
their rational use of health care resources. METHODS: The
Ofﬁce provides an organisational framework for the technology
assessment that forms the basis for the medicine subsidy
approval policy of the National Health Insurance Fund, and per-
forms the related medical and economic assessment duties. The
National Health Insurance Fund makes decisions regarding the
granting of subsidies for medicines, based on the ﬁndings pre-
sented by the Ofﬁce of HTA, which X determines the profes-
sional guidelines for analysing health technology, coordinates the
assessment of new and existing technologies, and issues instruc-
tions for the use of individual technologies X provides reliable
and undistorted information for the appraisal of individual pro-
cedures, comparing them with alternative opportunities for the
use of resources based on a combination of clinical evidence, efﬁ-
cacy and cost-effectiveness factors, X facilitates the appropriate
use of cost-effective health care technologies, and provides
support for decision-makers. RESULTS: The majority of appli-
cations were related to anti-tumour drugs and products designed
to treat diseases of the cardiovascular or central nervous system.
The Ofﬁce also performs problem-oriented comparative exami-
nations, such as the comprehensive policy study of Positron
Emission Tomography (PET) and Gamma-knife Surgery, Drug-
eluting Coronary Stents, etc. CONCLUSION: In the initial
period, staff at the Ofﬁce of Health Technology Assessment
focused primarily on assessments of medicines to determine their
eligibility for social insurance funding, but as the new institu-
tional structure becomes more ﬁrmly established, it is increas-
ingly able to perform thorough, comprehensive assessments of
other health technologies.
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EVALUATION OF SCIENTIFIC QUALITY OF POSTMARKETING
SURVEILLANCE STUDIES IN GERMANY
Dietrich ES, Zierold F
National association of statutory health insurance physicians, Berlin,
Germany
OBJECTIVES: Anwendungsbeobachtungen (AWBs) are a
common type of postmarketing surveillance studies in Germany.
They provide information about medical beneﬁt, safety, and
effectiveness of drugs in daily practice and can support reim-
bursement decisions. As practice based research gains in impor-
tance the scientiﬁc quality of AWBs was evaluated. METHODS:
The German drug law demands the reporting of AWBs to
NASHIP. In the examined six-month period (July to December
2005), 453 AWBs were announced to NASHIP. Onehun-
dredeighteen were announced for the ﬁrst time, the others were
supplementary information to ongoing AWBs. AWB-conducting
companies were asked for more detailed information and AWBs
designs were analysed by a validated data entry form that was
based on recommendations of the Federal Institute for Drugs and
Medical Devices for the conduct of AWBs. RESULTS: One
hundred-eight AWBs included statements about goals: 46%
listed drug utilisation, 87% safety, 68% effectiveness and 24%
QoL. Only a third of AWBs chose a suitable design, basically
those that examined safety and drug-utilisation. Only 10% were
comparative. Most evaluated drugs were high-priced up to costs
of Euro 4500 per prescription. Almost 50% of all drugs had
obtained marketing authorisation during the last ﬁve years.
Median observation time per patient was 140 days. Only 19%
of all AWBs mentioned a planned publication of results explic-
itly. CONCLUSIONS: This study showed the very heterogeneous
quality of AWBs in Germany. In most AWBs the marketing aspect
dominated obviously and they were not suitable for reimburse-
ment decisions on the basis of the price-beneﬁt ratio.
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COST-EFFECTIVENESS STUDY OF ADJUSTED CLINICAL
GROUPS TO ASSESS THE ABILITY OF SPANISH PRIMARY
CARE TEAMS TO BRING ISSUES TO RESOLUTION
Serrat J1, Sicras A2, Navarro R2, Ruano I3,Velasco S2
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OBJECTIVES: The aim of the study was to determine the cost-
effectiveness ratio of professionals in ﬁve Spanish primary care
teams (Spanish “EAPs”) on the basis of Adjusted Clinical Groups
(ACGs). METHODS: Retrospective descriptive study. We
included all patients attended by ﬁve EAPs in 2004. Principal
measurements: age, sex, consultation episodes/reasons, total
cost/expense (semi-ﬁxed: personnel, procurement; variable:
pharmaceutical expense, referrals, tests), department, centre,
physician in charge (Spanish “UBA”—basic care unit) and a
qualitative synthetic index (Spanish “ISC”) drawn from 36
process and outcome indicators relating to health care practice.
Every patient was assigned to an exclusive ACG/category. We
produced the adjusted efﬁciency index (Spanish “IE”) indicating
relative efﬁciency with reference to a standard (observed/
expected; grouper-6.0; Johns Hopkins University) and the 
ISC for each centre and UBA. We analysed the correlation of IE
and ISC (Spearman’s rank correlation) and a range of indirect
standardisations to adjust the results. Statistical signiﬁcance 
p < 0.05. RESULTS: We studied 81,085 patients (use intensity
76.9%), with a mean of 5.0 ± 3.6 and 8.0 ± 8.2 visits per patient
per year. The total cost per attended patient per year was 
340 euros (reference average relative weight). Pharmaceutical
prescription costs accounted for more than 60%. The efﬁciency
indices (IE) of the centres were: 0.92, 0.94, 0.95, 1.06, and 1.06
(p = 0.000). The qualitative synthetic indices (ISC) were: 68.9%,
66.1%, 45.8%, 43.4%, and 31.6% (p = 0.000). An inverse cor-
relation was found between IE and ISC (p < 0.001; R2 = 36%).
The explanatory power of the classiﬁcation was 53%. CON-
